AEON Biopharma discontinues Phase 2 migraine study after failed endpoints; CFO terminated, CEO takes PFO role

AEON Biopharma, Inc.

Phase 2 double-blind migraine study (episodic and chronic cohorts) discontinued; chronic cohort failed primary and secondary endpoints.
Open-label extension study also stopped; patients monitored for safety for 12 weeks post last treatment.
CEO Marc Forth appointed principal financial officer after termination of CFO Peter Reynolds effective May 17, 2024.
Jennifer Sy appointed principal accounting officer; no additional compensation for Forth or Sy.
Company to conserve cash and evaluate strategic options after study discontinuation.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Peter Reynolds

Chief Financial Officer

AEON · AEON Biopharma, Inc.

Effective: 2024-05-17
Filed: May 16, 2024, 7:59 PM ET

On May 16, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) terminated the Consulting Agreement (the “Agreement”) between AEON and Peter Reynolds, which has resulted in his termination as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company effective as of May 17, 2024.

Role change

Marc Forth

principal financial officer

AEON · AEON Biopharma, Inc.

Effective: 2024-05-17
Filed: May 16, 2024, 7:59 PM ET

On May 16, 2024, our Board of Directors appointed Marc Forth, age 53, as our principal financial officer, effective as of May 17, 2024.

Role change

Jennifer Sy

principal accounting officer

AEON · AEON Biopharma, Inc.

Effective: 2024-05-17
Filed: May 16, 2024, 7:59 PM ET

On May 16, 2024, our Board of Directors appointed Jennifer Sy, age 39, as our principal accounting officer, effective as of May 17, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Reynolds was terminated as Chief Financial Officer at AEON Biopharma, Inc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

On May 16, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) terminated the Consulting Agreement (the “Agreement”) between AEON and Peter Reynolds, which has resulted in his termination as the Chief Financial Officer, principal financial officer and principal accounting officer of the Company effective as of May 17, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Forth was appointed as principal financial officer at AEON Biopharma, Inc..

Action: appointed
Role: principal financial officer

Exact text from the filing

On May 16, 2024, our Board of Directors appointed Marc Forth, age 53, as our principal financial officer, effective as of May 17, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Sy was appointed as principal accounting officer at AEON Biopharma, Inc..

Action: appointed
Role: principal accounting officer

Exact text from the filing

On May 16, 2024, our Board of Directors appointed Jennifer Sy, age 39, as our principal accounting officer, effective as of May 17, 2024.

View on SEC.gov

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-24-000066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.